Rationale for a vaccine using cellular-derived epitope presented by HIV isolates

It has been clearly demonstrated that cellular antigens (HLA, β2-microglobulin) are incorporated at the virion surface. The same epitope derived from β2-microglobulin is presented on all virus isolates. The peptide was identified by blocking the neutralizing capacity of a monoclonal antibody directe...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 17; no. 13; pp. 1700 - 1705
Main Authors Galéa, Pascale, le Contel, Carole, Coutton, Christine, Chermann, Jean-Claude
Format Journal Article Conference Proceeding
LanguageEnglish
Published Oxford Elsevier Ltd 26.03.1999
Elsevier
Subjects
AIDS Vaccines - immunology
AIDS/HIV
Animals
Antibodies, Monoclonal - immunology
beta 2-Microglobulin - immunology
Biological and medical sciences
Cellular antigen
Disease progression
Epitopes
Fundamental and applied biological sciences. Psychology
HIV
HIV Antibodies - blood
Human immunodeficiency virus
Humans
Microbiology
Neutralizing antibodies
Rabbits
Vaccine
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Virology
Cellular antigen
Vaccine
HIV
Neutralizing antibodies
Disease progression
Virus
Antigenic determinant
Antibody
Major histocompatibility system
Retroviridae
Review
Human immunodeficiency virus
Lentivirus
Humoral immunity
β2-Microglobulin
Neutralization
Online AccessGet full text

Cover

More Information
Summary:It has been clearly demonstrated that cellular antigens (HLA, β2-microglobulin) are incorporated at the virion surface. The same epitope derived from β2-microglobulin is presented on all virus isolates. The peptide was identified by blocking the neutralizing capacity of a monoclonal antibody directed to R7V epitope: using this peptide for developing an ELISA, we have detected antibodies in nonprogressor patients with neutralizing property to laboratory strains and primary isolates. Purified anti-R7V antibodies immunoprecipitate all HIV isolates at concentration dependent. R7V is immunogenic after rabbit immunization and induces HIV immunoprecipitating and neutralizing antibodies. The patient's as well as the immunized rabbit antibodies did not bind to any cell. No autoimmune disease is found in nonprogressor patients. For all these reasons, R7V is a good candidate for an universal AIDS vaccine.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
ObjectType-Feature-3
ObjectType-Review-1
ISSN:0264-410X
1873-2518
DOI:10.1016/S0264-410X(98)00432-0